Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2013

View Archived Issues

Results presented for nanoliposomal irinotecan for the treatment of metastatic pancreatic cancer

The development of an optogenetic two-hybrid system for the control of mammalian gene transcription

Nuclear imaging of a novel radiolabeled probe for prostate cancer

Phase I study of GNX-5086 enrolls first healthy volunteer

Japanese researchers present new AMPA receptor modulators

Sareum Holdings patents novel agents for cancer

New cathepsin S and/or L inhibitors synthesized at Roche

Novel Der p 23 peptide-derived immunotherapy for house dust mite allergy

Researchers in China prepare new agents for HIV infection

Scientists in Germany disclose new agents for bacterial infections

Dainippon Sumitomo Pharma designs novel coagulation factor inhibitors

Subcutaneous Orencia launched in Japan for rheumatoid arthritis

Agenix and Arrayjet to jointly develop point-of-care diagnostic test

Spartan RX CYP2C19 assay receives FDA 510(k) clearance

Mount Sinai receives research grant for autism subtype study

BiondVax reports altered prime-boost strategy for its influenza vaccine

Orexigen receives DMC clearance to conduct interim analysis for the Light Study

OncoGenex reports Rainier trial initiation

Virttu Biologics treats first cohort in phase I/II mesothelioma study

Catalyst obtains FDA breakthrough therapy designation for Firdapse

Epilepsy treatment to be launched in Japan for partial-onset seizures

Health Canada approves Roche's Erivedge for advanced basal cell carcinoma

QRxPharma set to resubmit MoxDuo NDA

Medivir reports interim results from cohort 2 of COSMOS study

Bharat Biotech launches Typbar-TCV typhoid conjugate vaccine

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...